Your browser doesn't support javascript.
loading
Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B cell lymphoma treated with R-CHOP / 대한내과학회지
Korean Journal of Medicine ; : 52-59, 2009.
Article in Korean | WPRIM | ID: wpr-229434
ABSTRACT
BACKGROUND/

AIMS:

The International Prognostic Index (IPI) and absolute lymphocyte count (ALC) are prognostic factors in diffuse large B cell lymphoma (DLBCL). Nevertheless, in the Rituximab era, a new predictive marker related to Rituximab might be needed. We evaluated prognostic factors for survival in patients with early stage DLBCL after R-CHOP (Rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone) treatment.

METHODS:

From Aug 2003 to Nov 2007, 78 patients with early stage DLBCL, who finished R-CHOP as scheduled, were reviewed retrospectively. Survival analyses were performed according to clinical parameters (age, performance status, lactate dehydrogenase (LDH), extra-nodal involvement, stage, ALC, and the rates of reduction of the white blood count (WBC) and ALC).

RESULTS:

Of the 78 patients with early stage DLBCL, 26 (33.3%) were classified as stage I. Seventy-three patients (93.6%) presented with a good performance status, while LDH was elevated in 20 patients (25.6%). According to the IPI, 67 (85.9%), 8 (10.3%), and 3 (3.8%) patients were classified in the low, low-intermediate, and high-intermediate risk groups, respectively. The overall response rate was 100%, including a 94.8% complete response. Survival analysis demonstrated that the rate of reduction of ALC following the first cycle of the R-CHOP regimen was the only factor associated with time-to-progression (p=0.037), whereas age was the single most important prognostic factor for overall survival (p=0.006).

CONCLUSIONS:

In our study, the rate of reduction of ALC in addition to age and IPI was found to be a significant prognostic factor in patients with early stage DLBCL treated with the R-CHOP regimen.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Vincristine / Lymphocytes / Doxorubicin / Retrospective Studies / Lymphoma, B-Cell / Lymphocyte Count / Cyclophosphamide / Antibodies, Monoclonal, Murine-Derived / Rituximab / L-Lactate Dehydrogenase Type of study: Observational study / Prognostic study Limits: Humans Language: Korean Journal: Korean Journal of Medicine Year: 2009 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Vincristine / Lymphocytes / Doxorubicin / Retrospective Studies / Lymphoma, B-Cell / Lymphocyte Count / Cyclophosphamide / Antibodies, Monoclonal, Murine-Derived / Rituximab / L-Lactate Dehydrogenase Type of study: Observational study / Prognostic study Limits: Humans Language: Korean Journal: Korean Journal of Medicine Year: 2009 Type: Article